Akimi Akashi

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations

Takeshi Yamaura, Toshiyuki Nakatani, Ken Uda et al. · Blood · 2017 · 143 citations

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells

Fangli Chen, Yuichi Ishikawa, Akimi Akashi et al. · Oncotarget · 2016 · 39 citations · Full text

Hematological Malignancy, Tumor Biology, Flt3 Inhibitor +13

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study

Naomi Kawashima, Akimi Akashi, Yasunobu Nagata et al. · Annals of Hematology · 2018 · 25 citations

Hematological Malignancy, Jalsg Aml201 Study, Genetic Disorder +9

Mutation analysis of therapy-related myeloid neoplasms

Takahiro Nishiyama, Yuichi Ishikawa, Naomi Kawashima et al. · Cancer Genetics · 2018 · 22 citations

Hematological Malignancy, Medicine, Hematology +5

Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells

Naomi Kawashima, Yuichi Ishikawa, Jeong Hui Kim et al. · Nature Communications · 2022 · 22 citations · Full text